Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022
Cash & Equivalents	53.5	102.53
Short-Term Investments	23.47	-
Cash & Cash Equivalents	76.97	102.53
Cash Growth	-24.93%	-
Receivables	1.76	0.53
Other Current Assets	1.09	1.62
Total Current Assets	79.82	104.68
Property, Plant & Equipment	8.1	8.39
Goodwill and Intangibles	16.55	19.23
Other Long-Term Assets	0.65	0.76
Total Long-Term Assets	25.29	28.38
Total Assets	105.11	133.05
Accounts Payable	0.61	1.1
Deferred Revenue	-	10.89
Current Debt	3.6	3.49
Other Current Liabilities	8.02	10.15
Total Current Liabilities	12.23	25.63
Long-Term Debt	13.32	15.96
Other Long-Term Liabilities	25.17	15.75
Total Long-Term Liabilities	38.49	31.71
Total Liabilities	50.72	57.34
Total Debt	16.91	19.45
Debt Growth	-13.04%	-
Retained Earnings	-181.31	-152.59
Comprehensive Income	0.31	-
Shareholders' Equity	-162.02	-140.7
Net Cash / Debt	60.06	83.08
Net Cash / Debt Growth	-27.71%	-
Working Capital	67.59	79.05

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).